HighTower Advisors LLC Sells 23,863 Shares of IQVIA Holdings Inc. (NYSE:IQV)

HighTower Advisors LLC lowered its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 118,168 shares of the medical research company’s stock after selling 23,863 shares during the period. HighTower Advisors LLC owned about 0.07% of IQVIA worth $23,221,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IQV. Raymond James Financial Inc. bought a new position in IQVIA in the 4th quarter valued at approximately $236,120,000. FMR LLC increased its position in IQVIA by 38.7% in the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in shares of IQVIA during the third quarter valued at $147,683,000. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Finally, Nordea Investment Management AB increased its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after purchasing an additional 452,029 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on IQV shares. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a report on Wednesday. UBS Group reduced their target price on IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Morgan Stanley raised their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a report on Tuesday, February 11th. Citigroup reduced their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Barclays lowered their target price on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Up 2.2 %

IQVIA stock opened at $185.40 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $32.69 billion, a P/E ratio of 24.72, a P/E/G ratio of 1.99 and a beta of 1.50. The firm has a 50 day moving average price of $196.63 and a 200-day moving average price of $210.95. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $256.34.

IQVIA (NYSE:IQV) last released its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.